Program cell death 1 (PD1)/PD-Ligand 1(PD-L1) immune checkpoint pathway is another druggable target for MM immunotherapy and IMiDs enhanced the anti-MM activity of anti-PD1 or anti-PD-L1 MoAbs in a preclinical study [38]. The gene discussed is CD274; the disease is Miyoshi myopathy.